Multiple myeloma and cancer: Is there a D-lightful connection?

American Journal of Hematology

Volumn 84, Issue 7, 2009, Pages 393-394

  Holick, Michael F ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ERGOCALCIFEROL; PARATHYROID HORMONE; VITAMIN D;

BREAST CANCER; CANCER RISK; COLORECTAL CANCER; DISEASE ASSOCIATION; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; MULTIPLE MYELOMA; NEOPLASM; NOTE; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; PROSTATE CANCER; SKIN CANCER; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MULTIPLE MYELOMA; NEOPLASM STAGING; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 67649723448     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21450     Document Type: Note

References (32)

1. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-281.
2. Moan J, Porojnicu AC, Dahlback A, Setlow RB. Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. Proc Natl Acad Sci USA 2008;105:668-673. (Pubitemid 351171766)
3. Pittas AG, Dawson-Hughes B, Li T, et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006;29:650-656. (Pubitemid 44115368)
4. Ginde AA, Mansbach JM, Camargo CA. Association between serum 25- hydroxyvitamin D level and upper respiratory tract infection in the third national health and nutrition examination survey. Arch Intern Med 2009; 169:384-390.
5. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117:503-511.
6. Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: A review. Altern Med Rev 2005;10:94-111. (Pubitemid 40911119)
7. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005;26:662-687. (Pubitemid 41127276)
8. Christakos S, Dhawan P, Liu Y, et al. New insights into the mechanisms of vitamin D action. J Cell Biochem 2003;88:695-705. (Pubitemid 36258819)
9. Tangpricha V, Flanagan JN, Whitlatch LW, et al. 25-hydroxyvitamin D-1α-hydroxylase in normal and malignant colon tissue. Lancet 2001;357:1673-1674. (Pubitemid 32568244)
10. 3 by a human small cell lung cell line. J Clin Endocrinol Metab 1994;79:554-560.
11. Bikle DD, Nemanic MD, Whitney JO, Elias PO. Neonatal human foreskin keratinocytes produce 1,25-dihydroxyvitamin D3. Biochemistry 1986;25:1545-1548. (Pubitemid 16013928)
12. 3-1-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 2001;66:287-292.
13. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Sciencexpress 2006;3:1770-1773.
14. Apperly FL. The relation of solar radiation to cancer mortality in North America. Cancer Res 1941;1:191-195.
15. Garland C, Shekelle RB, Barrett-Connor E, et al. Dietary vitamin D and calcium and risk of colorectal cancer: A 19-year prospective study in men. Lancet 1985;9:307-309. (Pubitemid 15157126)
16. Garland FC, Garland CF, Gorham ED, Young JF. Geographic variation in breast cancer mortality in the United States: A hypothesis involving exposure to solar radiation. Prev Med 1990;19:614-622.
17. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006; 354:684-696. (Pubitemid 43247139)
18. Holick MF. Calcium plus vitamin D and the risk of colorectal cancer. N Engl J Med 2006;354:2287. (Pubitemid 43788150)
19. Knight JA, Lesosky M, Barnett H, et al. Vitamin D and reduced risk of breast cancer: A population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007;16:422-499. (Pubitemid 46548644)
20. Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. Am J Clin Nutr 2007;85:1586-1591. (Pubitemid 46890428)
21. 3 inhibits angiogenesis in vitro and in vivo. Circ Res 2000;87:214-220.
22. Ng AC, Kumar SK, Rajkumr V, Drake MT. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am J Hematol, in press.
23. Chapuy MC, Schott AM, Garnero P, et al. Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. J Clin Endocrinol Metab 1996;81:1129-1133. (Pubitemid 26083981)
24. Thomas KK, Lloyd-Jones DH, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998;338:777-783. (Pubitemid 28135983)
25. Holick MF, Siris ES, Binkley N, et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005;90:3215-3224. (Pubitemid 41014278)
26. Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003;22:142-146. (Pubitemid 36417827)
27. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Biophys Mol Biol 2006;92:39-48. (Pubitemid 43831966)
28. Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc 2003; 78:1463-1470. (Pubitemid 37475629)
29. Holick MF. Vitamin D deficiency: What a Pain it is. Mayo Clin Proc 2003; 78:1457-1459.
30. Grey A, Lucas J, Horne A, et al. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 2005;90:2122-2126. (Pubitemid 40586249)
31. Adams JS, Hewison M. Hypercalcemia caused by granuloma-forming disorders. In: Favus MJ, editor. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 6th ed. Washington, DC: American Society for Bone and Mineral Research; 2006. pp 200-202.
32. Tangpricha V, Colon NA, Kaul H, et al. Prevalence of vitamin D deficiency in patients attending an outpatient cancer care clinic in Boston. Endocr Pract 2004;10:292.